FDA Sends Mixed Message On Labeling Authority: Is Website Enough?
Executive Summary
FDA's planned "Drug Watch" website could render proposals to give the agency authority to mandate drug labeling changes and postmarketing safety studies unnecessary, FDA Acting Deputy Commissioner for Operations Janet Woodcock told the Senate Health Committee
You may also be interested in...
Elidel, Protopic Get Boxed Warnings On Cancer, But Not At Top Of Labeling
Boxed warnings about potential cancer risks will appear in the warning sections for Novartis' Elidel (pimecrolimus) and Astellas' Protopic (tacrolimus)
Elidel, Protopic Get Boxed Warnings On Cancer, But Not At Top Of Labeling
Boxed warnings about potential cancer risks will appear in the warning sections for Novartis' Elidel (pimecrolimus) and Astellas' Protopic (tacrolimus)
Elidel, Protopic “Black Box” Could Be Test Of FDA’s Labeling Authority
FDA's proposal to add a "black box" to labeling of the eczema treatments Elidel and Protopic could be a high-profile test of the agency's ability to change product labeling following recent congressional discussion of the agency's authority